WP 1.1
Creation of improved platforms
This will focus on cell engineering tools and improving immunogenicity by optimising production and purification methods and by using novel encapsulation approaches. For VLPs vaccines we will use a modular platform to ensure compatibility and flexibility. Recombinant vaccines against bacterial pathogens will also be developed as an exemplar, using a novel Protein-Glycan Conjugation Technology.
WP 1.2
Rapid and responsive development and manufacture
The potential for the technologies researched in WP1.1 to be exploited as platform technologies will be explored and their adaptability to new antigen targets studied. Automated microscale bioprocessing coupled with advanced laboratory automation and modelling will be used alongside engineering fundamentals to mimic the whole manufacturing process at short notice which could be deployed to support pandemic
response.
WP 1.3
Needle-free and thermostable formulation
Injectable vaccines do not generate sufficient immune responses at the portals of pathogen entry and alternative routes of administration must be established which could provide faster administration with less carbon footprint impact than plastic disposables. In this WP, alternative mucosal routes of immunisation will be investigated, and formulations tailored for these sites developed for some of the Hub vaccine
technologies. A range of adjuvants will also be tested.
WP 2.1
Understanding bioprocess sustainability impact
We will produce a "best practice" document to ensure that the scope and preparation of the life cycle inventory can be refined so that outputs are meaningful. This will facilitate hotspot analysis or decision-making in process design. Secondly, we will source data and boost the range of well-defined inputs to enable more precise life cycle
inventories reflective of the actual materials used in bioprocesses.
WP 2.2
Exploring industrial symbiosis and circular economy of resources
We will investigate how future facilities might be embedded within a circular economy and aim to address three key aspects around the use of waste and novel facility design: a) Identification of waste streams and location of future manufacturing. b) Biopharmaceutical waste streams as a future resource. c) Design of facilities to enable effective use of waste streams.
